BETA
Florida medical device developer and brand owner of botanical hydrogel wound dressings and skin barrier products.
Lavior Pharma develops and markets botanical wound-care and skin-barrier products for consumers and healthcare professionals. Founded in 2010 by Gilad and Anabelle Savion, the Florida company is led by Gilad as CEO and Anabelle as COO. Its registered business address is in Hallandale Beach.
The range combines hydrogel formulations with the company’s AGS-RIED botanical extract from Inula viscosa. Lavior describes control of cultivation, harvesting and extraction and markets its products as made in the USA. FDA lists the company as a specification developer for the hydrogel range. Consumer tubes and larger professional formats serve wound-care practices, distributors and home-care users.
A 65-patient randomized study published in the Journal of Wound Care in July 2025 compared Lavior Diabetic Wound Gel with SoloSite. It reported comparable wound-closure times, with improvements in some patient-reported measures. Lavior also partners with Lovell Government Services to expand access through federal healthcare procurement channels.
FDA lists Lavior Pharma as a specification developer for its hydrogel wound-dressing and barrier-care range. The listed NAE category is Class I and exempt from 510(k) premarket notification. Current product records identify the diabetic wound hydrogel, multipurpose wound gel, post-surgical barrier gel and diabetic skin barrier cream under this category; these are device listings, rather than individual FDA clearance decisions. [17][15][1][2][4][3]
Current labeling separates wound moisture management from care of closed incisions and dry, intact skin. The Diabetic Skin Barrier Cream is specifically described as a non-medicated skin-care product, not a treatment for open wounds. Professional “Advanced” tubes and consumer tubes are marketed in different sizes within the respective product lines. [6][13][9]
Latest recorded source review: 2026-11-03.
Scope: selected product families.
Documented commercial product families.
Botanical hydrogel dressing designed to maintain a moist wound environment. The range includes a 1 fl oz consumer tube and the 3 fl oz Advanced Diabetic Wound Hydrogel for professional supply. [10][1][17]
Commercially available · Listed exempt device family
Botanical wound gel for maintaining a moist, protected wound surface. Sold in a 1 fl oz consumer format and a 3 fl oz Advanced MultiCare Hydrogel professional format. [11][2][17]
Commercially available · Listed exempt device family
Gel for protecting and moisturizing recovering skin after procedures. The consumer product is directed to closed incisions; a 3 fl oz Advanced Post-Procedure Skin Barrier Gel is offered to professionals. [12][4][17]
Commercially available · Listed exempt device family
Daily-use cream for dry, intact skin, including feet, legs and hands. It is separate from the wound hydrogel range and is not intended for open wounds. [13][3][17]
Commercially available · Listed exempt device familyLavior and Lovell Government Services announced a partnership serving federal healthcare procurement channels. [19]
Journal of Wound Care published a six-week comparison involving 65 patients. Wound-closure times were comparable between groups. [14]
Accessed 11/03/2026
Last substantive review: 11/3/2026